Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
Posted inDermatology news Oncology

Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma

The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short median times to recurrence or metastasis, substantial resource needs, and meaningful proportions of untreated metastatic episodes.
Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis
Posted inAllergy & Immunology Dermatology news

Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis

Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the epithelial barrier theory and prompt integrated clinical awareness and mechanistic research.
Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship
Posted inDermatology news

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship

A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting antibiotic-associated dysbiosis may reduce biologic persistence.
Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery
Posted inDermatology news Psychiatry

Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery

A double‑blind RCT in 160 healthy adults found that intranasal oxytocin combined with structured positive interaction and daily physical intimacy (affectionate touch, sex) was associated with reduced cortisol and modestly faster dermatologic wound healing, with caveats on robustness and generalizability.
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Posted inDermatology news Oncology

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectable cutaneous squamous cell carcinoma.
Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
Posted inDermatology news Oncology

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism

A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a two‑hit, T‑cell–mediated model and urging cautious coprescribing and prospective study.
Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs
Posted inDermatology news

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs

Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and fewer adverse events than deucravacitinib through 24 weeks.